Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)
Conditions:   Hepatocellular Carcinoma (HCC);   Unresectable Hepatocellular Carcinoma
Interventions:   Drug: Yttrium-90;   Device: Selective Internal Radiation Therapy;   Radiation: Stereotactic Body Radiation Therapy;   Diagnostic Test: PET/CT;   Device: Therasphere
Sponsors:   University of Michigan Rogel Cancer Center;   Department of Health and Human Services
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 29, 2020 / by / in
Comments